Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Letter

Effect of erythropoietin therapy on clinical outcome in patients after acute ischemic stroke: a debatable issue

Chun-Man Yuen1, Cheuk-Kwan Sun23, Steve Leu45 and Hon-Kan Yip45*

Author Affiliations

1 Division of Trauma, Department of Surgery, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niaosong District, Kaohsiung City, 833, Taiwan

2 Division of General Surgery, Department of Surgery, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niaosong District, Kaohsiung City, 833, Taiwan

3 Department of Emergency Medicine, E-Da Hospital, I-Shou University, Kaohsiung City, 824, Taiwan

4 Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niaosong District, Kaohsiung City, 833, Taiwan

5 Center for Translational Research in Biomedical Sciences, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niaosong District, Kaohsiung City, 833, Taiwan

For all author emails, please log on.

Critical Care 2011, 15:425  doi:10.1186/cc10145


See related research by Yip et al., http://ccforum.com/content/15/1/R40, and related commentary by Minnerup et al., http://ccforum.com/content/15/2/129

Published: 17 May 2011

First paragraph (this article has no abstract)

Our recent clinical trial has shown that erythropoietin (EPO) therapy significantly increased circulating endothelial progenitor cell (EPC) levels and was strongly associated with favorable 90-day clinical outcomes after ischemic stroke (IS) [1]. Contrary to the findings of our study [1] and of others [2,3], the randomized phase II/III German Multicenter EPO Stroke Trial [4], which is currently the largest clinical study on EPO treatment in patients with IS, not only failed to show any additional benefit but also demonstrated increased mortality after combined therapy with EPO and tissue plasminogen activator (tPA) [4]. Interestingly, subgroup analysis of the study revealed that EPO therapy improved 90-day clinical outcome in patients without additional tPA therapy [4]. In this way, the findings from the subgroup analysis of that study [4] corroborate those of our clinical trial [1].